搜索结果11-20 的 26010 / ������������KA���:ZA31���24������ ���������������������������������

  1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma.

  2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma.

  3. Frequently Asked Questions - 妙佑医疗国际

    Medicare or Medicaid does not qualify for copay assistance programs. You are being treated with specific medicines as listed by the drug manufacturer. What are ...

  4. Mayo Clinic Urology Physician Update - June 2023

    Page 1.

  5. Mayo Clinic Cancer Physician Update - July 2022

    Page 1.

  6. 神经科 - 临床试验 - 妙佑医疗国际

    Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ...

  7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma.

  8. Untitled

    Page 1. Page 2. Page 3. Page 4.

  9. Mayo Clinic Physician Update - June 2023

    Page 1.

  10. Mayo Clinic Ophthalmology Physician Update - August 2023

    Page 1.